An interventional study of Terbutaline in Fetal Distress, sponsored by Stanford University. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-03-08.
Sponsored by Stanford University · Not applicable, Interventional, and Treatment
To compare nitroglycerin and terbutaline for intrapartum fetal heart rate resuscitation
35 studies on the registry are indexed under Fetal Distress; 7 are open to participants now.
This study's enrollment of 110 is close to the median of 113 across 24 interventional studies indexed under Fetal Distress.
Browse Fetal Distress studies →Stanford University is the lead sponsor of 2,117 studies on the registry; 425 are open to participants now.
Of its 259 completed or terminated interventional studies of FDA-regulated products, 197 (76%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria::
Drug: Terbutaline
Drug: Terbutaline
Terbutaline 250 micrograms intravenously for intrapartum fetal resuscitation. Nitroglycerine 400 micrograms intravenously for intrapartum fetal resuscitation.
resolution of abnormal fetal heart tracing
Time frame: Administration of study medication to resolution of abnormal fetal heart tracing or operative delivery.
cesarean section rate
Time frame: Data analysis
operative vaginal delivery rate
Time frame: Data analysis
neonatal outcomes
Time frame: time of delivery to time of discharge
This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stanford University